IFNA1 and cancer: Treatment with neoadjuvant immunotherapy in mouse models suggest that iRECs could potentially be more sensitive to it14; however, prolonged IFN signaling can promote resistance associated with cancer cells epigenetically acquiring immunological memory that promotes immune dysfunction.22